Home Stock

Stock Research: SCI Pharmtech

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

SCI Pharmtech

TAI:4119 TW0004119003
35
  • Value
    20
  • Growth
    34
  • Safety
    Safety
    66
  • Combined
    28
  • Sentiment
    54
  • 360° View
    360° View
    35
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

SCI Pharmtech, Inc. is a Taiwan-based company focused on manufacturing and selling Active Pharmaceutical Ingredients (APIs). The company operates in the pharmaceutical industry, producing APIs, API intermediates, and special chemicals. It distributes its products in Taiwan, Europe, the Americas, and other parts of Asia. In the last fiscal year, the company had a market cap of $254 million, profits of $13 million, and revenue of $46 million. The number of employees is not available.

more

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock SCI Pharmtech are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for SCI Pharmtech. The consolidated Sentiment Rank has a good rank of 54, which means that professional investors are more optimistic about the stock than for 54% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 66 or better than 66% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 20, meaning that the share price of SCI Pharmtech is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 34. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Market Pulse
Country Taiwan
Industry Pharmaceuticals
Size Small
Website sci-pharmtech.com.tw
Index
SCI Pharmtech stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 20-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
20 22 16 35
Growth
34 74 97 83
Safety
Safety
66 27 51 88
Sentiment
54 8 20 37
360° View
360° View
35 7 36 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
14 12 25 28
Opinions Change
50 50 50 50
Pro Holdings
n/a 32 38 55
Market Pulse
85 1 1 n/a
Sentiment
54 8 20 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
20 22 16 35
Growth
34 74 97 83
Safety Safety
66 27 51 88
Combined
28 27 56 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
20 18 9 20
Price vs. Earnings (P/E)
19 14 42 20
Price vs. Book (P/B)
72 31 29 48
Dividend Yield
1 44 21 75
Value
20 22 16 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
60 94 49 83
Profit Growth
43 70 100 23
Capital Growth
65 18 95 84
Stock Returns
11 56 71 65
Growth
34 74 97 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
69 41 55 96
Refinancing
27 24 21 35
Liquidity
75 49 78 100
Safety Safety
66 27 51 88

Similar Stocks

Discover high‑ranked alternatives to SCI Pharmtech and broaden your portfolio horizons.

Inpex

TYO:1605
Country: Japan
Industry: Oil & Gas Production
Size: X-Large
Full Stock Analysis

Tripod Technology

TAI:3044
Country: Taiwan
Industry: Electronic Components
Size: Medium
Full Stock Analysis

Wistron

TAI:3231
Country: Taiwan
Industry: Technology Hardware & Peripherals
Size: Large
Full Stock Analysis

Highwealth Construction

TAI:2542
Country: Taiwan
Industry: Real Estate Development
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews